Loading
Telisotuzumab Vedotin / Non Small Cell Lung Cancer · Phase 2 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration for telisotuzumab vedotin, a c-Met-targeting antibody–drug conjugate, in adults with previously treated c-Met–overexpressing NSCLC. The trial is actively recruiting and has not yet reported results; no efficacy or safety data are available in this registry record.
Phase 2, Interventional, Randomized, Parallel, Open label, Treatment purpose. Non-Small Cell Lung Cancer; age from 18 Years. Intervention: Telisotuzumab Vedotin Dose A; Telisotuzumab Vedotin Dose B; Telisotuzumab Vedotin Dose C. n = 150. 80 sites across 7 countries.
This is a Phase 2 trial registration for telisotuzumab vedotin, a c-Met-targeting antibody–drug conjugate, in adults with previously treated c-Met–overexpressing NSCLC. The trial is actively recruiting and has not yet reported results; no efficacy or safety data are available in this registry record.
This is a registry record only; no safety or efficacy results have been reported. Specific adverse event rates, response rates, and pharmacokinetic data are not available and cannot be assessed from this source.
The source did not state who this applies to in practice.
This is an active Phase 2 trial registration with no results reported; the study is designed to assess safety and efficacy of telisotuzumab vedotin in previously treated NSCLC but enrollment and follow-up are ongoing.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06568939). This is a study registration, not published results. Lead sponsor: AbbVie. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 150 participants (ESTIMATED). Conditions: Non-Small Cell Lung Cancer. Interventions: DRUG: Telisotuzumab Vedotin. Primary outcome measures: Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2) , Up to Approximately 3 Years; Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD) , Up to Approximately 3 Years; Percentage of Participants with Treatment-Emergent Peripheral Neuropathy , Up to Approximately 3 Years; Percentage of Participants with Treatment-Emergent Ocular Surface Disorders , Up to Approximately 3 Years; Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation , Up to Approximately 3 Years; Percentage of Participants with Grade 5 Treatment-Emergent AEs , Up to Approximately 3 Years; Objective Response (OR) by Blinded Independent Central Review (BICR) , Up to Approximately 3 Years. Brief summary: Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide. Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.